Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis

Immune checkpoint inhibitors (ICIs) in combination withother anti-cancer treatments have been approved for a variety of cancers. While the difference in the incidence of cardiovascular adverse events has not been fully investigated. We aimed to assess the the differences in cardiotoxicity among canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Maobai, Cheng, Xitong, Ni, Ruping, Zheng, Bin, Huang, Shunmin, Yang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515416/
https://www.ncbi.nlm.nih.gov/pubmed/36189211
http://dx.doi.org/10.3389/fimmu.2022.1006860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515416/
https://www.ncbi.nlm.nih.gov/pubmed/36189211
http://dx.doi.org/10.3389/fimmu.2022.1006860

Ejemplares similares